Cardiology - Global Cardiology Academy

257-272 of 394

Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
MinuteCE®
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
Valeria Caso, MD, PhD
1.00 program credit
- Valeria Caso, MD, PhD
1.00 program credit
Tailoring Treatment for Optimal Outcomes in Patients With AAV
Tailoring Treatment for Optimal Outcomes in Patients With AAV
MinuteCE®
Tailoring Treatment for Optimal Outcomes in Patients With AAV
Bernhard Hellmich, MD; Andreas Kronbichler, MD
0.75 program credits
- Bernhard Hellmich, MD
- Andreas Kronbichler, MD
0.75 program credits
How Do We Translate Real-World AF Data Into Everyday Clinical Practice?
How Do We Translate Real-World AF Data Into Everyday Clinical Practice?
MinuteCE®
How Do We Translate Real-World AF Data Into Everyday Clinical Practice?
Renato D. Lopes, MD, MHS, PhD; Valeria Caso, MD, PhD
1.00 program credit
- Renato D. Lopes, MD, MHS, PhD
- Valeria Caso, MD, PhD
1.00 program credit
How Do We Translate Real-World VTE Data Into Everyday Clinical Practice for Ongoing Anticoagulation?
How Do We Translate Real-World VTE Data Into Everyday Clinical Practice for Ongoing Anticoagulation?
MinuteCE®
How Do We Translate Real-World VTE Data Into Everyday Clinical Practice for Ongoing Anticoagulation?
Alexander T. Cohen, MD, MBBS
1.00 program credit
- Alexander T. Cohen, MD, MBBS
1.00 program credit
Patient Case Study: Obesity and VTE
Patient Case Study: Obesity and VTE
MinuteCE®
Patient Case Study: Obesity and VTE
Renato D. Lopes, MD, MHS, PhD; Alexander T. Cohen, MD, MBBS
1.00 program credit
- Renato D. Lopes, MD, MHS, PhD
- Alexander T. Cohen, MD, MBBS
1.00 program credit
Patient Case Study: Obesity
Patient Case Study: Obesity
MinuteCE®
Patient Case Study: Obesity
Renato D. Lopes, MD, MHS, PhD; Valeria Caso, MD, PhD
1.00 program credit
- Renato D. Lopes, MD, MHS, PhD
- Valeria Caso, MD, PhD
1.00 program credit
Trade off: Ischemic/Thrombotic vs Bleeding  
Trade off: Ischemic/Thrombotic vs Bleeding  
MinuteCE®
Trade off: Ischemic/Thrombotic vs Bleeding  
Renato D. Lopes, MD, MHS, PhD
1.00 program credit
- Renato D. Lopes, MD, MHS, PhD
1.00 program credit
Implementing the SOC Induction Therapies in AAV 
Implementing the SOC Induction Therapies in AAV 
MinuteCE®
Implementing the SOC Induction Therapies in AAV 
Silke R. Brix, MD, MRCP, SCPR; Bernhard Hellmich, MD
0.75 program credits
- Silke R. Brix, MD, MRCP, SCPR
- Bernhard Hellmich, MD
0.75 program credits
Setting the Stage of Real-World Data vs RCT
Setting the Stage of Real-World Data vs RCT
MinuteCE®
Setting the Stage of Real-World Data vs RCT
Renato D. Lopes, MD, MHS, PhD
1.00 program credit
- Renato D. Lopes, MD, MHS, PhD
1.00 program credit
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: VTE Considerations
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: VTE Considerations
MinuteCE®
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: VTE Considerations
Alexander T. Cohen, MD, MBBS
1.00 program credit
- Alexander T. Cohen, MD, MBBS
1.00 program credit
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Spotlight On ATTR-CM
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Spotlight On ATTR-CM
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
CME/CE
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD; Stephen J. Greene, MD
0.25 credits
- Mikhail Kosiborod, MD
- Stephen J. Greene, MD
0.25 credits
Pulmonary Hypertension in COPD: Insights into Diagnosis and Treatment
Pulmonary Hypertension in COPD: Insights into Diagnosis and Treatment
On the Frontlines of COPD
Pulmonary Hypertension in COPD: Insights into Diagnosis and Treatment
Arun Jose, MD
- Arun Jose, MD
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
CME/CE
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn Lam, MD, PhD; Scott Solomon, MD
0.50 credits
- Carolyn Lam, MD, PhD
- Scott Solomon, MD
- Mikhail Kosiborod, MD
0.50 credits
How Artificial Sweeteners Could Be Linked to Heart Disease
How Artificial Sweeteners Could Be Linked to Heart Disease
Heart Matters
How Artificial Sweeteners Could Be Linked to Heart Disease
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA; Wilson Tang, MD
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Wilson Tang, MD

17/11